放射增效剂Ⅱ号致突变性研究

MUTAGENICITY RESEARCH OF No.Ⅱ DRUG

目的与方法 :用Ames试验、CHO_K细胞染色体畸变试验及微核试验对Ⅱ号药进行了致突变性研究。 结果 :Ames试验在1～5000μg/皿剂量范围内加与不加S9 条件下 ,4个菌株的回变菌落数均未有2倍以上的增加 ;微核试验显示在25～125mg/kg剂量 ,小鼠骨髓嗜多染红细胞微核细胞率(MNCF)与对照组比较无显著性差异(P>0.05) ;CHO_K细胞染色体畸变试验显示在不加S9 条件下 ,31～250μg/ml剂量范围内染色体畸变率小于5 %,在加S9 条件下250μg/ml剂量组畸变率为8 %,属可疑阳性。 结论 :Ames试验和微核试验均为阴性 ,在高剂量组加S9 条件下 ,染色体畸变率为可疑阳性 ,表明在高剂量条件下 。

Purpose and methods: The mutagenicity of No.Ⅱdrug was examined using Ames test, CHO_K cell chromosome aberration test and micronucleus test. Results: No.Ⅱ drug in the dose range of 1～5 000 μg / plate did not increase the number of reversion mutation in any of the 4 strains with or without S 9 in Ames test. The frequencies of micronuclear cell(MNCF) in PCE did not increase with dose of 25～125 mg / kg in micronucleus test. In CHO_K cell chromosome aberration test, the result was suspiciously positive because the frequency of chromosome aberration increased to 8 % with the dose of 250 μg / ml with S 9. Conclusion: The results of No.Ⅱ drug in Ames test and micronucleus test were negative, and at higher dose in chromosome aberration test the result was suspiciously positive.[